[Efficacy of plasma exchange combined with fetal hepacyties on viral hepatitis gravis].
To evaluate the efficacy of mid-artificial liver support system (ALSS) on viral hepatitis gravis. One hundred and thirty eight patients with hepatitis gravis were treated with plasma exchange combined with fetal hepacyties, fifty six patients were treated with plasma exchange and other forty eight patients were treated with fetal hepacyties respectively. The liver function was examined in all patients before ALSS. The liver function, amino acid spectrum and cardiac muscle enzyme were examined before and after ALSS in patients treated with plasma exchange and fetal hepacyties. It showed that the survival rate of the patients treated with plasma exchange combined with fetal hepacyties was higher than that of the patients only treated with plasma exchange or fetal hepacyties (P < 0.01). The liver function, BCAA/AAA ratio and cardiac muscle enzyme also significantly changed in patients treated with plasma exchange and fetal hepacyties before and after ALSS (p < 0.01 or 0.05). Plasma exchange combined with fetal hepacyties can effectively treat viral hepatits gravis.